Takeda Pharmaceutical Company L
TAK · Healthcare
$18.23
Cargando gráfico…
Noticias
Últimos titulares de esta acción
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
A $1,000 investment in Halozyme Therapeutics made in September 2016 would be worth $10,866.33 as of September 1, 2026, representing a 986.63% gain. The biopharmaceutical company's success is driven by its ENHANZE drug delivery technology licensed to major pharma partners like Roche, Takeda, J&J, and AbbVie, generating royalties that comprise over 55% of revenues. While strong demand for partnered drugs and new collaboration deals support growth, biosimilar competition for blockbuster drugs and dependence on partner revenues present risks.
Fabry Disease Treatment Market 2026-2031 - Growth Driven by Increasing Adoption of Enzyme Replacement Therapy
The global Fabry disease treatment market is projected to grow from USD 2.63 billion in 2025 to USD 4.09 billion by 2031, with a CAGR of 7.63%. Growth is driven by expanded screening identifying more patients, advances in gene and mRNA therapies, and sustained enzyme replacement therapy demand. However, high treatment costs remain a significant barrier to patient access, particularly in emerging markets. Asia-Pacific is expected to record the fastest growth at 8.28% CAGR.